Latest Stock Buy or Sell? Make More Informed Decisions!
Today, The Panic-Proof Portfolio (Stockchase Research) and Paul Gardner, CFA commented about whether L-T, AP.UN-T, XRB-T, BTB.UN-T, TA-T, BPY.UN-T, BCE-T, CSH.UN-T, BRK.B-N, BEI.UN-T, CJT-T, WIR.UN-T, ENB-T, TRP-T, REI.UN-T, ZAG-T, WN-T, VSC-T, VIAC-Q, UMC-N, MRNA-Q are stocks to buy or sell.
- Page 1/2
- Next Page
Premium content
TOP PICK
Stockchase Research Editor: Michael O'Reilly MRNA is now a well known name in the production of COVID-19 vaccine and is only one of three that have received approval in the US. Purchase agreements amounted to $18 billion, allowing cash flow reserves of the company to balloon. The company is now working on a single-dose product that does not require extreme refrigeration. The pullback in the share price, and a forward PE of 9x earnings, offers a good entry level here. We would buy this with a stop loss at $90, looking to achieve $175 -- upside potential of 29%. Yield 0% (Analysts’ price target is $174.25)
Pharma & Healthcare
Premium content
TOP PICK
Stockchase Research Editor: Michael O'Reilly The semiconductor space saw global chip sales up over 14% last year and there is now a global shortage of supply. UMC is a Taiwan based chip producer and recently released sales were up 14%. It has beat earnings estimates in each of the past three reporting cycles. It trades at 31x earnings, cheap compared to its peers at 68x. It also pays a small dividend. We would buy this with a stop loss at $7, looking achieve $11.50 -- upside potential over 20%. Yield 1.56% (Analysts’ price target is $11.55)
Technology
Premium content
TOP PICK
Stockchase Research Editor: Michael O'Reilly VIAC is a media monster. Recently reported earnings beat analyst expectations and showed streaming sales were up over 70% and operating cash flow was $2.2 billion and cash reserves are now over $3 billion. Recent stock price volatility has been associated to a forced liquidation by hedge fund that impacted several other unrelated entities. This creates a good entry point as it is now trading at under 20x earnings, compared to peers at over 45x. It pays a modest dividend, backed by a payout ratio under 25% of cash flow. We would buy this with a stop loss at $25, looking to achieve $57.50 -- upside potential over 32%. Yield 2.19% (Analysts’ price target is $57.48)
Broadcasting
COMMENT
Bond yields. They could go either way in the year ahead. Big question is do we see a test of 2%? A real chance that we could see higher rates, and then the market has to start paying attention. If the 10-year gets to 2%, it gets interesting. A game of chicken. Does the Fed do curve control, which pins down the rates in the yield curve and causes a lot of distortion? But we're not there yet. Probably 9-12 months before the Fed starts to talk about tapering or lifting rates.
COMMENT
Investment grade or high yield bonds? For the last year, he's focused on credit spread. There's been very little value. He's buying mostly short-term, under 3-4 years, and focusing on government yield curve. Risk that rates drop from these heights and a chance we run into a recession. He's neutral in his spot, and negative on credit. Not a great entry point for a great yield experience.
BUY
With rising rates, bonds are not ideal. It comes down to risk/return. You might not get a great rate of return, but you preserve capital. If the stock market trades off quickly, the bond market will trade higher. He'd hold his nose and realize that everyone needs a bit of bonds to stabilize their life.
E.T.F.'s
